Sudeep Pharma IPO Opens on November 21; Price Band Set At ₹563–₹593

Vadodara, November 20: Sudeep Pharma IPO opens for subscription on November 21. The company has announced that it has set the Sudeep Pharma IPO price band at ₹563 to ₹593. The ₹895 crore Sudeep Pharma IPO is a combination of fresh issue of 0.16 crore shares aggregating to ₹95 crores and offer for sale of 1.35 crore shares aggregating to ₹800 crores.

The lot size is 25 shares per application, with a minimum investment amount by a retail investor at ₹14.825 (25 shares) at the upper price band. The lot size investment for sNII is 14 lots (350 shares), amounting to ₹2,07,550, and for bNII, it is 68 lots (1,700 shares), amounting to ₹10,08,100. ICICI Securities Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.

Sudeep Pharma is an Indian company that is engaged in the manufacturing of mineral-based excipients and active ingredients. The company serves the Pharmaceutical, Food, and Nutrition industries globally. It is recognised as one of India’s leading producers of mineral-based ingredients, which are essential components in medicines and fortified food products.

Sudeep Pharma Financial Snapshot

As of 30 June 2025, the company had assets of ₹922.26 crore, higher than ₹717.17 crore in March 2025, ₹513.87 crore in March 2024, and ₹420.11 crore in March 2023. Total income was at ₹130.08 crore in June 2025, compared to ₹511.33 crore in March 2025, ₹465.38 crore in March 2024, and ₹438.26 crore in March 2023. Profit after tax was ₹31.27 crore in June 2025, lower from ₹138.69 crore in March 2025 and ₹133.15 crore in March 2024, However, it was higher than the ₹62.32 crore in March 2023.

Sudeep Pharma IPO Utilisation of Funds

Sudeep Pharma will use ₹78.8 crore from the IPO proceeds for procurement of machinery for the company’s production line at its Nandesari Facility I. The balance amount will be used for general corporate purposes.

What’s Ahead for Sudeep Pharma IPO?

Sudeep Pharma IPO opens for subscription on November 21, and will close on November 25. The Sudeep Pharma IPO allotment status is expected to be finalised on November 26. The company is expected to credit the shares and initiate refunds on November 27. The shares of the company will tentatively list on NSE and BSE on November 28. The company is a leading producer of mineral-based ingredients, and has reported good financials. Investors will hope for a strong investor demand when it opens for subscription, followed by a stellar listing on NSE and BSE.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations